Compare Moderna, Inc. (MRNA) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs D Wave Quantum Inc — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while D Wave Quantum Inc trades at $20.95 (market cap $7.53B). The key difference: Moderna, Inc. is far larger — about 3.2× D Wave Quantum Inc's market cap, and Moderna, Inc. is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| MRNA | QBTS | |
|---|---|---|
Market Cap | $24.18B | $7.53B |
Sector | Health | Technology |
52-Week High | $81.80 | $44.78 |
52-Week Low | $22.36 | $12.98 |
Enterprise Value | $20.33B | $7.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
D-Wave Quantum (QBTS) trades at $20.57, up 1.86% on the day, with a bearish technical signal despite unanimous analyst buy ratings. The stock exhibits extreme valuation metrics, including a P/S ratio of 583.84, while fundamentals show deep losses with a net income margin of -2001.59% in 2026. Recent Q2 2026 earnings missed revenue estimates but highlighted a 1120% surge in bookings, per Barrons on August 6, 2026.
The outlook hinges on commercial adoption of quantum computing, offering speculative upside with a consensus price target of $38.29, but high execution risks and cash burn pose significant threats to shareholder value amid volatile sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
